gemopharm.ru
About company
The lead asset is the monoclonal antibody based on a proprietary therapeutic platform to target CD71 selectively in the tumor microenvironment. Gemopharm’s approach mitigates potential toxicities that may occur from solicitation of non-selective complement dependent cytotoxicity (CDC) activation or addition of a toxin payload. Gemopharm has generated in vivo proof-of-concept data demonstrating substantial efficacy and validating the mechanism of action of the lead candidate. The pilot toxicology has been completed without any signs of toxicity (no mortalities, clinical signs, or DLTs observed). Gemopharm envisages that its lead candidate can address a high unmet need for effective therapies for relapsed/refractory primary and secondary central nervous system (CNS) and intraocular lymphomas (IOL).
